Gufic Biosciences LimitedPharmaceuticals & HealthcareGUFICBIO
Q1 FY27 concall · earnings callGufic Biosciences Limited
Gufic Biosciences delivered strong Q1 growth driven by improved margins from its new Indore plant, progress on complex injectable capabilities, and a strategic shift in its international business model.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Total Revenue from Operations | ₹260.8 Cr | vs ₹226.9 Cr YoY | |
| EBITDA | ₹47.2 Cr | vs ₹33.2 Cr YoY | |
| EBITDA Margin | 18.09% | vs 14.6% YoY | |
| Profit After Tax | ₹22.46 Cr | vs ₹12.1 Cr YoY | |
| PAT Margin | 8.61% | vs 5.3% YoY |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹207.79 Cr+3% YoY+1.8% QoQ | ₹19.31 Cr-13.3% YoY-11.3% QoQ | ₹1.93-13.5% YoY-11.1% QoQ |
| Q2 FY25 | ₹204.18 Cr-5% YoY+0.7% QoQ | ₹21.77 Cr-6.2% YoY+4.4% QoQ | ₹2.17-9.2% YoY+4.3% QoQ |
| Q1 FY25 | ₹202.81 Cr— YoY+4% QoQ | ₹20.86 Cr— YoY+4% QoQ | ₹2.08— YoY+4% QoQ |
| Q4 FY24 | ₹194.99 Cr— YoY-3.4% QoQ | ₹20.05 Cr— YoY-9.9% QoQ | ₹2.00— YoY-10.3% QoQ |
| Q3 FY24 | ₹201.78 Cr— YoY-6.1% QoQ | ₹22.26 Cr— YoY-4.1% QoQ | ₹2.23— YoY-6.7% QoQ |
TL;DR
- Revenue grew to INR260.8 Cr in Q1 FY27 from INR226.9 Cr in Q1 FY26.
- EBITDA margin improved to 18.09% from 14.6%.
- Indore plant utilization is increasing; depot and liposomal product lines nearing completion.
- International model shifting from B2B distributor-led to B2C IP-led in key emerging markets.
- GLP-1 CMO operations with Hetero started, expected to gain traction in Q2 and Q3.
- Aesthetic division expanded with filler partnership, aiming to strengthen market position.
Said on the call
“So 15% to 20% is what we commit to you that would be a bare minimum.”
From the Q&A
| Topic | What management said |
|---|---|
| GLP-1 CMO Contribution | Management clarified CMO operations for Hetero started in Q1 with residual revenues; expects traction in Q2 and Q3, aiming for 30% domestic and 70% international capacity use by year-end. |
| International Business Model Shift | Explained shift from distributor-led (B2B) to IP-led (B2C) model in Africa, Southeast Asia, and South Asia, with new team recruitment, aiming for higher margins and building own IP. |
| Indore Plant Capacity & Margins | Indore capacity utilization expected to reach 40-45% by year-end from ~30-35% currently; EU certification pending, which will improve margins; peak revenue without further capex estimated at INR 1,600-2,000 Cr depending on product mix. |
| Aesthetic Division Filler Launch | Partnered with Revanesse Prollenium for fillers; expects registration by Q2/Q3 and launch by December or January, aiming to strengthen #2 position in toxin and target #1 in toxin and fillers in 3-5 years. |
| Growth Guidance | Management committed to 15-20% year-on-year growth as a bare minimum, with efforts to grow beyond that. |
| Employee Addition Strategy | Majority of recent employee additions linked to Indore plant ramp-up and international expansion; some were previously contract workers brought on payroll for consistency. |
Guidance
- Target 15-20% year-on-year revenue growth as a minimum.
- Indore capacity utilization to reach 40-45% by year-end.
- EU certification for Indore expected in the next 1-2 months.
- GLP-1 CMO operations to gain traction in Q2 and Q3.
- Filler product launch expected by December 2026 or January 2027.
- International B2C model to be rolled out in key emerging markets.
Source
Summary written from the transcript filed by Gufic Biosciences Limited for the call held on 17 Aug 2026; published 22 Aug 2026, 15:22 IST.
More Q1 FY27 concalls ·How verification works ·Report an error